




【Fig. 1】




【Fig. 2】



【Fig. 3】



【Fig. 4】



Comentarios para pET303 CT-His

5369 nucleótidos

Promotor de T7: bases 20-36

Sitio de cebado del promotor: bases 20-39

Operador lac (*lacO*): bases 39-63

Sitio de unión de ribosoma (RBS): bases 95-100

Marca 6X His: bases 119-136

Sito de cebado inverso de T7: bases 186-206

Región de terminación de la transcripción: bases 147-277

Origen de F1: bases 287-742

Promotor de *bla*: bases 775-879


Gen de resistencia a ampicilina (*bla*): bases 874-1734

Origen pB R322: bases 1945-2678 (c)

ORF *ROP*: bases 2920-3011 (c)


ORF *lacI*: bases 3914-5032 (c)

[Fig. 5]




Tiafenacilo

【Fig. 6】




Flumioxazina




【Fig. 7】


Pomesafeno



【Fig. 9】




【Fig. 10】




Piraclonilo


Sulfentrazona




【Fig. 12】




【Fig. 13】




【Fig. 14】




【Fig. 15】




【Fig. 16】




【Fig. 17】




【Fig. 18】




【Fig. 19】




【Fig. 20】




【Fig. 21】




【Fig. 22】




【Fig. 23】



【Fig. 24】




【Fig. 25】




【Fig. 26】


Vector de fusión de proteína PPO y MBP (proteína de unión a maltosa)




【Fig. 27】




【Fig. 28】




【Fig. 29】




【Fig. 30】




【Fig. 31】



【Fig. 32】




【Fig. 33】




【Fig. 34】

Tiafenacilo




【Fig. 35】

Saflufenacilo




【Fig. 36】


Fomesafeno




【Fig. 37】




【Fig. 38】




【Fig. 39】




【Fig. 40】






【Fig. 41】

【Fig. 42】



【Fig. 43】




【Fig. 44】

CyPPO8 F363M


Tipo salvaje #3 #6




【Fig. 45】




【Fig. 46】





【Fig. 47】




【Fig. 48】



【Fig. 49】



【Fig. 50】




【Fig. 51】

T₀ soja transgénica, Cy2YM


T₁ soja transgénica, Cy8FM

CyPPO2 Y373M

CyPPO8 F363M





【Fig. 52】



Antes del tratamiento


Después del tratamiento

【Fig. 53】



【Fig. 54】


Antes de tratamiento con Tiafenacilo 10 μ M



7° día después de tratamiento con Tiafenacilo 10 μ M

【Fig. 55】

Antes de tratamiento con Saflufenacilo 10 μ M



7º día después de tratamiento con Saflufenacilo 10 μ M

【Fig. 56】

